Results of interferon-free hepatitis C therapy in the Czech Republic in real-life

Czech version

Authors: P. Husa ¹; L. Husová ²
Authors‘ workplace: Klinika infekčních chorob LF MU a FN Brno ¹; Centrum kardiovaskulární a transplantační chirurgie Brno ²
Published in: Gastroent Hepatol 2016; 70(6): 500-507
Category: Hepatology
doi: https://doi.org/10.14735/amgh2016500

Overview

The first real-life data regarding the efficacy of interferon-free therapy for chronic hepatitis C in the Czech Republic are presented. Patients were treated with the combined therapy of paritaprevir/ritonavir plus ombitasvir plus dasabuvir with or without ribavirin. There were 109 patients, who were predominantly men (62, 57%). Most patients were infected by subtype 1b (101, 93%); six patients (5%) had subtype 1a infections and two patients (2%) had genotype 4 infections. Both treatment-naive (43/109, 39%) and pegylated interferon- and ribavirin-experienced patients (66/109, 61%) were treated. A sustained virological response 12 weeks after therapy termination was achieved in 107 patients (98.2%). After excluding two patients from the analyses for reasons other than virological treatment failure, the treatment efficacy was 100%.

Key words:
chronic hepatitis C – paritaprevir/ritonavir – ombitasvir – dasabuvir – ribavirin

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
7. 11. 2016

Accepted:
20. 11. 2016

Sources

1. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2016. Summary. [online]. Available from: www.easl.eu/ medias/ cpg/ HCV2016/ Summary.pdf.

2. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61(2): 373–395. doi: 10.1016/ j.jhep. 2014.05.001

3. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63(1): 199–236. doi: 10.1016/ j.jhep.2015.03.025.

4. AASLD recommendation for testing, managing, and treating hepatitis C. [online]. Available from: www.hcvguidelines.org.

5. Urbánek P, Husa P, Šperl J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Klin Mikrobiol Infekc Lek 2015; 21(3): 83–98.

6. Urbánek P. Exviera, Viekirax. Gastroent Hepatol 2015; 69(1): 75–80. doi: 10.14735/ amgh201575.

7. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/ r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1594–1603. doi: 10.1056/ NEJMoa1315722.

8. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/ r, ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370(21): 1983–1992. doi: 10.1056/ NEJMoa1402338.

9. Wyles DL, Sulkowski MS, Eron JJ et al.TURQUOISE-I: 94% SVR12 in HCV/ HIV-1coinfected patients treated with ABT-450/ r/ ombitasvir, dasabuvir and ribavirin. Hepatology 2014; 60 (Suppl 1): 136A.

10. Zeuzem S, Jacobson IM, Baykal T et al.Retreatment of HCV with ABT-450/ r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1604–1614. doi: 10.1056/ NEJMoa1401561.

11. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147(2): 359–365. doi: 10.1053/ j.gastro.2014.04.045.

12. Poordad F, Hezode C, Trinh R et al. ABT--450/ r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370(21): 1973–1982. doi: 10.1056/ NEJMoa1402869.

13. Feld JJ, Moreno C, Trinh R et al. Sustained virological response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/ paritaprevir/ r and dasabuvir for 12 weeks. J Hepatol 2016; 64(2): 301–307. doi: 10.1016/ j.jhep.2015.10.005.